JP2013543896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543896A5 JP2013543896A5 JP2013541010A JP2013541010A JP2013543896A5 JP 2013543896 A5 JP2013543896 A5 JP 2013543896A5 JP 2013541010 A JP2013541010 A JP 2013541010A JP 2013541010 A JP2013541010 A JP 2013541010A JP 2013543896 A5 JP2013543896 A5 JP 2013543896A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- methyl
- lupus erythematosus
- systemic lupus
- dimethylcyclohex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (12)
- (a)4−(4−{[2−(4−クロロフェニル)−4,4−ジメチルシクロヘキサ−1−エン−1−イル]メチル}ピペラジン−1−イル)−N−({3−ニトロ−4−[(テトラヒドロ−2H−ピラン−4−イルメチル)アミノ]フェニル}スルホニル)−2−(1H−ピロロ[2,3−b]ピリジン−5−イルオキシ)ベンズアミドまたはこの医薬的に許容される塩;或いは
(b)4−(4−{[2−(4−クロロフェニル)−4,4−ジメチルシクロヘキサ−1−エン−1−イル]メチル}ピペラジン−1−イル)−N−[(4−{[(trans−4−ヒドロキシ−4−メチルシクロヘキシル)メチル]アミノ}−3−ニトロフェニル)スルホニル]−2−(1H−ピロロ[2,3−b]ピリジン−5−イルオキシ)ベンズアミドまたはこの医薬的に許容される塩
である化合物の、全身性エリテマトーデス、ループス腎炎またはシェーグレン症候群を治療するための医薬の製造における使用。 - 0.001mg/kg〜1000mg/kgの範囲の治療的有効量で用いられる、請求項1に記載の使用。
- 0.01mg/kg〜500mg/kgの範囲の治療的有効量で用いられる、請求項2に記載の使用。
- 0.1mg/kg〜300mg/kgの範囲の治療的有効量で用いられる、請求項3に記載の使用。
- 1mg/kg〜100mg/kgの範囲の治療的有効量で用いられる、請求項4に記載の使用。
- 前記化合物を所望の部位に対して作用をさらに改善するために、結合タンパク質と組み合わせて用いる、請求項1に記載の使用。
- 前記化合物が、4−(4−{[2−(4−クロロフェニル)−4,4−ジメチルシクロヘキサ−1−エン−1−イル]メチル}ピペラジン−1−イル)−N−({3−ニトロ−4−[(テトラヒドロ−2H−ピラン−4−イルメチル)アミノ]フェニル}スルホニル)−2−(1H−ピロロ[2,3−b]ピリジン−5−イルオキシ)ベンズアミドまたはこの医薬的に許容される塩である、請求項1〜6のいずれか一項に記載の使用。
- 全身性エリテマトーデスまたはループス腎炎を治療するための、請求項7に記載の使用。
- 全身性エリテマトーデスを治療するための、請求項8に記載の使用。
- 前記化合物が、4−(4−{[2−(4−クロロフェニル)−4,4−ジメチルシクロヘキサ−1−エン−1−イル]メチル}ピペラジン−1−イル)−N−[(4−{[(trans−4−ヒドロキシ−4−メチルシクロヘキシル)メチル]アミノ}−3−ニトロフェニル)スルホニル]−2−(1H−ピロロ[2,3−b]ピリジン−5−イルオキシ)ベンズアミドまたはこの医薬的に許容される塩である、請求項1〜6のいずれか一項に記載の使用。
- 全身性エリテマトーデスまたはループス腎炎を治療するための、請求項10に記載の使用。
- 全身性エリテマトーデスを治療するための、請求項11に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41668910P | 2010-11-23 | 2010-11-23 | |
US61/416,689 | 2010-11-23 | ||
PCT/US2011/061769 WO2012071374A1 (en) | 2010-11-23 | 2011-11-22 | Methods of treatment using selective bcl-2 inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016007618A Division JP6215368B2 (ja) | 2010-11-23 | 2016-01-19 | 選択的bcl−2阻害薬を用いた処置方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013543896A JP2013543896A (ja) | 2013-12-09 |
JP2013543896A5 true JP2013543896A5 (ja) | 2015-01-15 |
JP5876067B2 JP5876067B2 (ja) | 2016-03-02 |
Family
ID=45218888
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013541010A Expired - Fee Related JP5876067B2 (ja) | 2010-11-23 | 2011-11-22 | 選択的bcl−2阻害薬を用いた処置方法 |
JP2016007618A Expired - Fee Related JP6215368B2 (ja) | 2010-11-23 | 2016-01-19 | 選択的bcl−2阻害薬を用いた処置方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016007618A Expired - Fee Related JP6215368B2 (ja) | 2010-11-23 | 2016-01-19 | 選択的bcl−2阻害薬を用いた処置方法 |
Country Status (36)
Country | Link |
---|---|
US (5) | US20120129853A1 (ja) |
EP (2) | EP2642999B1 (ja) |
JP (2) | JP5876067B2 (ja) |
KR (3) | KR20180030257A (ja) |
CN (2) | CN105664164B (ja) |
AR (1) | AR083946A1 (ja) |
AU (2) | AU2011332000B2 (ja) |
BR (1) | BR112013012854B1 (ja) |
CA (1) | CA2820618C (ja) |
CL (1) | CL2013001458A1 (ja) |
CR (1) | CR20130268A (ja) |
CY (1) | CY1118442T1 (ja) |
DK (1) | DK2642999T3 (ja) |
DO (1) | DOP2017000056A (ja) |
EC (1) | ECSP13012710A (ja) |
ES (2) | ES2603129T3 (ja) |
GT (1) | GT201300136A (ja) |
HR (1) | HRP20161762T1 (ja) |
HU (1) | HUE031267T2 (ja) |
IL (2) | IL226490A (ja) |
LT (1) | LT2642999T (ja) |
MX (1) | MX346201B (ja) |
MY (2) | MY165884A (ja) |
NZ (2) | NZ610746A (ja) |
PH (1) | PH12016500939B1 (ja) |
PL (1) | PL2642999T3 (ja) |
PT (1) | PT2642999T (ja) |
RS (1) | RS55545B1 (ja) |
RU (1) | RU2593231C2 (ja) |
SG (2) | SG190399A1 (ja) |
SI (1) | SI2642999T1 (ja) |
TW (2) | TWI620736B (ja) |
UA (2) | UA119150C2 (ja) |
UY (1) | UY33746A (ja) |
WO (1) | WO2012071374A1 (ja) |
ZA (1) | ZA201303589B (ja) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
CA3154024C (en) | 2010-06-03 | 2024-02-27 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
US20120277210A1 (en) | 2010-10-29 | 2012-11-01 | Abbott Laboratories | Solid dispersions containing an apoptosis-inducing agent |
NZ610151A (en) | 2010-11-23 | 2015-06-26 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
ES2603129T3 (es) | 2010-11-23 | 2017-02-23 | Abbvie Ireland Unlimited Company | Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2 |
KR20140119023A (ko) | 2011-12-13 | 2014-10-08 | 버크 인스티튜트 포 리서치 온 에이징 | 의료 요법을 개선하는 방법 |
MX2015001081A (es) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
US9539251B2 (en) | 2012-09-07 | 2017-01-10 | Genentech, Inc. | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
US20150241429A1 (en) * | 2012-09-11 | 2015-08-27 | Hospital For Special Surgery | Irhom2 inhibition for the treatment of complement mediated disorders |
EP3293185A1 (en) | 2013-03-13 | 2018-03-14 | AbbVie Inc. | Processes for the preparation of an apoptosis-inducing agent |
US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
CN106163557B (zh) | 2014-01-28 | 2020-07-14 | 巴克老龄化研究所 | 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物 |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US11331328B2 (en) * | 2014-05-05 | 2022-05-17 | Bioventures, Llc | Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents |
DK3179991T3 (da) | 2014-08-11 | 2021-12-06 | Acerta Pharma Bv | Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
WO2017027571A1 (en) | 2015-08-10 | 2017-02-16 | Dana-Farber Cancer Institute, Inc. | Mechanism of resistance to bet bromodomain inhibitors |
KR102124715B1 (ko) | 2015-11-03 | 2020-06-18 | 제넨테크, 인크. | 암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물 |
CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
LT3494115T (lt) | 2016-08-05 | 2021-01-25 | The Regents Of The University Of Michigan | N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai |
CN110759908B (zh) * | 2017-06-26 | 2021-03-12 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 |
US11480568B2 (en) * | 2017-09-28 | 2022-10-25 | Yeda Research And Development Co. Ltd. | Diagnosis of autoimmune diseases |
KR20200108302A (ko) | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
US11478469B2 (en) | 2018-07-31 | 2022-10-25 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases |
TWI725488B (zh) | 2018-07-31 | 2021-04-21 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途 |
KR20200139139A (ko) | 2018-07-31 | 2020-12-11 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | 리툭시맙 및/또는 벤다무스틴과 병용된 Bcl-2 억제제 또는 CHOP와 병용된 Bcl-2 억제제의 시너지적 항종양 효과 |
CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
KR20210061356A (ko) | 2018-09-18 | 2021-05-27 | 시그널켐 라이프사이언시즈 코포레이션 | 혈액암 치료를 위한 조합요법 |
CN112888687B (zh) | 2018-10-29 | 2023-01-24 | 正大天晴药业集团股份有限公司 | 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂 |
WO2020238785A1 (zh) | 2019-05-24 | 2020-12-03 | 正大天晴药业集团股份有限公司 | 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂 |
CN112707900B (zh) * | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
CN113444078B (zh) * | 2020-03-25 | 2023-07-07 | 中国科学院上海有机化学研究所 | 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用 |
BR112022021441A2 (pt) | 2020-04-24 | 2022-12-13 | Genentech Inc | Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits |
CN115397825A (zh) | 2020-04-29 | 2022-11-25 | 正大天晴药业集团股份有限公司 | 三氟甲基和氯双取代的磺酰胺类选择性bcl-2抑制剂的晶体 |
WO2022037684A1 (en) * | 2020-08-21 | 2022-02-24 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating systemic lupus erythematosus |
WO2022216942A1 (en) | 2021-04-07 | 2022-10-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
CN117377672A (zh) | 2021-06-04 | 2024-01-09 | 正大天晴药业集团股份有限公司 | 三氟甲基取代的磺酰胺类化合物的磷酸酯 |
IT202100025976A1 (it) | 2021-10-06 | 2023-04-06 | Univ Degli Studi Di Perugia | Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1) |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2128208A (en) | 1937-02-27 | 1938-08-23 | Du Pont | Alkoxy derivatives of methacrylic acid esters and method of producing them |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
JPH11512429A (ja) | 1995-09-15 | 1999-10-26 | ファルマシア・アンド・アップジョン・カンパニー | アミノアリールオキサゾリジノン n−オキシド |
HU230048B1 (hu) | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
DE69940063D1 (de) | 1998-07-06 | 2009-01-22 | Bristol Myers Squibb Co | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin |
WO2000004901A1 (en) * | 1998-07-21 | 2000-02-03 | Thomas Jefferson University | Small molecule inhibitors of bcl-2 proteins |
DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
WO2001047891A1 (fr) | 1999-12-28 | 2001-07-05 | Eisai Co., Ltd. | Composes heterocylciques contenant des groupes de sulfamide |
UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
DK1401806T3 (da) | 2001-06-06 | 2006-11-27 | Lilly Co Eli | Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
US20090247613A1 (en) | 2002-02-20 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
ATE465738T1 (de) | 2002-02-26 | 2010-05-15 | Astrazeneca Ab | Neue kristalline formen der krebsbekämpfenden verbindung zd1839 |
NZ534513A (en) | 2002-02-26 | 2007-04-27 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
JO2479B1 (en) | 2002-04-29 | 2009-01-20 | ميرك شارب اند دوم ليمتد | Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine |
JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
DE602004009344T2 (de) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | Neues verfahren zur herstellung von linezolid und verwandten verbindungen |
EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
CN101048140B (zh) | 2004-08-27 | 2013-06-19 | 拜尔保健公司 | 用于治疗癌症的药物组合物 |
JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
KR101509440B1 (ko) | 2005-05-12 | 2015-04-07 | 애브비 바하마스 리미티드 | 아폽토시스 촉진제 |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
CA2608333A1 (en) | 2005-05-16 | 2006-11-23 | Irm Llc | Pyrrolopyridine derivatives as protein kinase inhibitors |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
EP1893612B1 (en) | 2005-06-22 | 2011-08-03 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
CA2631760A1 (en) | 2005-12-02 | 2007-06-07 | Robert A. Brodsky | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
US7842681B2 (en) | 2006-09-05 | 2010-11-30 | Abbott Laboratories | Treatment of myeoproliferative diseases |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
CA2676944C (en) | 2007-02-15 | 2016-01-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
US8536157B2 (en) | 2007-04-13 | 2013-09-17 | The University Of Melbourne | Non-steroidal compounds |
BRPI0810362A2 (pt) | 2007-04-19 | 2014-10-29 | Concert Pharmaceuticals Inc | Compostos de morfolinila deuterados |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
WO2009039553A1 (en) * | 2007-09-27 | 2009-04-02 | The Walter And Eliza Hall Institute Of Medical Research | Benzothiazole compounds |
CA2701172A1 (en) * | 2007-10-01 | 2009-04-09 | The Johns Hopkins University | Methods of treating neurological autoimmune disorders with cyclophosphamide |
US9267033B2 (en) | 2007-10-01 | 2016-02-23 | Arkema Inc. | Blends of biodegradable polymers and acrylic copolymers |
EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
WO2009052443A1 (en) * | 2007-10-19 | 2009-04-23 | Burnham Institute For Medical Research | Naphthalene-based inhibitors of anti-apoptotic proteins |
CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
NZ585085A (en) | 2007-11-16 | 2012-08-31 | Abbott Lab | Method of treating arthritis using arylsulfonamide compounds |
CA2708223A1 (en) | 2007-12-06 | 2009-06-11 | Andrew Krivoshik | Oral compositions of abt-263 for treating cancer |
CN101481363B (zh) * | 2008-01-10 | 2011-05-04 | 江苏豪森药业股份有限公司 | 一种制备瑞格列奈的方法 |
WO2009091912A2 (en) | 2008-01-15 | 2009-07-23 | Abbott Laboratories | Improved mammalian expression vectors and uses thereof |
EP2296664A1 (en) * | 2008-04-15 | 2011-03-23 | Burnham Institute for Medical Research | An inhibitor of anti-apoptotic proteins |
EP2346495B2 (en) | 2008-10-07 | 2023-05-24 | Kudos Pharmaceuticals Limited | Pharmaceutical formulation 514 |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8586754B2 (en) * | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
PT2376480T (pt) * | 2008-12-05 | 2016-10-26 | Abbvie Inc | Derivados de sulfonamida como agentes indutores de apoptose seletivos de bcl-2 para o tratamento do cancro e de doenças imunes |
WO2010077740A2 (en) | 2008-12-09 | 2010-07-08 | Cytokine Pharmasciences, Inc. | Novel antiviral compounds, compositions, and methods of use |
WO2010072734A2 (en) | 2008-12-23 | 2010-07-01 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Targeting prodrugs and compositions for the treatment of gastrointestinal diseases |
KR20110116161A (ko) | 2009-01-19 | 2011-10-25 | 아보트 러보러터리즈 | 암, 면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제 |
AU2010204554B2 (en) | 2009-01-19 | 2013-05-30 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
CN109966294A (zh) * | 2009-05-26 | 2019-07-05 | 艾伯维爱尔兰无限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
TWI471321B (zh) | 2009-06-08 | 2015-02-01 | Abbott Gmbh & Co Kg | Bcl-2族群抑制劑之口服醫藥劑型 |
TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
US20120277210A1 (en) | 2010-10-29 | 2012-11-01 | Abbott Laboratories | Solid dispersions containing an apoptosis-inducing agent |
NZ610151A (en) | 2010-11-23 | 2015-06-26 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
ES2603129T3 (es) | 2010-11-23 | 2017-02-23 | Abbvie Ireland Unlimited Company | Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2 |
-
2011
- 2011-11-22 ES ES11793928.0T patent/ES2603129T3/es active Active
- 2011-11-22 ES ES16153335T patent/ES2701603T3/es active Active
- 2011-11-22 SG SG2013040167A patent/SG190399A1/en unknown
- 2011-11-22 AU AU2011332000A patent/AU2011332000B2/en not_active Ceased
- 2011-11-22 KR KR1020187007228A patent/KR20180030257A/ko active Application Filing
- 2011-11-22 BR BR112013012854-2A patent/BR112013012854B1/pt not_active IP Right Cessation
- 2011-11-22 SI SI201131050A patent/SI2642999T1/sl unknown
- 2011-11-22 CA CA2820618A patent/CA2820618C/en not_active Expired - Fee Related
- 2011-11-22 EP EP11793928.0A patent/EP2642999B1/en active Active
- 2011-11-22 DK DK11793928.0T patent/DK2642999T3/en active
- 2011-11-22 MY MYPI2013700925A patent/MY165884A/en unknown
- 2011-11-22 MX MX2013005849A patent/MX346201B/es active IP Right Grant
- 2011-11-22 TW TW105100832A patent/TWI620736B/zh not_active IP Right Cessation
- 2011-11-22 NZ NZ610746A patent/NZ610746A/en not_active IP Right Cessation
- 2011-11-22 AR ARP110104338A patent/AR083946A1/es unknown
- 2011-11-22 UA UAA201607110A patent/UA119150C2/uk unknown
- 2011-11-22 KR KR1020137016217A patent/KR101841084B1/ko active IP Right Grant
- 2011-11-22 CN CN201610007260.0A patent/CN105664164B/zh not_active Expired - Fee Related
- 2011-11-22 PT PT117939280T patent/PT2642999T/pt unknown
- 2011-11-22 WO PCT/US2011/061769 patent/WO2012071374A1/en active Application Filing
- 2011-11-22 LT LTEP11793928.0T patent/LT2642999T/lt unknown
- 2011-11-22 PL PL11793928T patent/PL2642999T3/pl unknown
- 2011-11-22 UY UY0001033746A patent/UY33746A/es not_active Application Discontinuation
- 2011-11-22 RU RU2013128544/14A patent/RU2593231C2/ru active
- 2011-11-22 US US13/301,898 patent/US20120129853A1/en not_active Abandoned
- 2011-11-22 NZ NZ708508A patent/NZ708508A/en not_active IP Right Cessation
- 2011-11-22 EP EP16153335.1A patent/EP3028702B1/en active Active
- 2011-11-22 RS RS20161159A patent/RS55545B1/sr unknown
- 2011-11-22 SG SG10201509631SA patent/SG10201509631SA/en unknown
- 2011-11-22 JP JP2013541010A patent/JP5876067B2/ja not_active Expired - Fee Related
- 2011-11-22 CN CN201180065747.XA patent/CN103402521B/zh not_active Expired - Fee Related
- 2011-11-22 UA UAA201307893A patent/UA113157C2/uk unknown
- 2011-11-22 HU HUE11793928A patent/HUE031267T2/en unknown
- 2011-11-22 KR KR1020197027331A patent/KR20190109590A/ko active Application Filing
- 2011-11-22 MY MYPI2017000882A patent/MY191300A/en unknown
- 2011-11-22 TW TW100142779A patent/TWI535701B/zh not_active IP Right Cessation
-
2013
- 2013-05-16 ZA ZA2013/03589A patent/ZA201303589B/en unknown
- 2013-05-21 IL IL226490A patent/IL226490A/en active IP Right Grant
- 2013-05-22 GT GT201300136A patent/GT201300136A/es unknown
- 2013-05-22 CL CL2013001458A patent/CL2013001458A1/es unknown
- 2013-06-07 CR CR20130268A patent/CR20130268A/es unknown
- 2013-06-21 EC ECSP13012710 patent/ECSP13012710A/es unknown
-
2014
- 2014-11-06 US US14/535,070 patent/US9345702B2/en active Active
-
2016
- 2016-01-19 JP JP2016007618A patent/JP6215368B2/ja not_active Expired - Fee Related
- 2016-04-22 US US15/136,582 patent/US9872861B2/en active Active
- 2016-05-20 PH PH12016500939A patent/PH12016500939B1/en unknown
- 2016-06-27 AU AU2016204396A patent/AU2016204396B2/en not_active Ceased
- 2016-12-13 CY CY20161101289T patent/CY1118442T1/el unknown
- 2016-12-21 HR HRP20161762TT patent/HRP20161762T1/hr unknown
-
2017
- 2017-03-03 DO DO2017000056A patent/DOP2017000056A/es unknown
- 2017-04-20 IL IL251845A patent/IL251845B/en active IP Right Grant
- 2017-12-12 US US15/838,605 patent/US20180369250A1/en not_active Abandoned
-
2019
- 2019-05-17 US US16/415,515 patent/US20200222413A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013543896A5 (ja) | ||
HRP20161762T1 (hr) | Postupci liječenja primjenom selektivnih bcl-2 inhibitora | |
JP2017527578A5 (ja) | ||
JP2013531028A5 (ja) | ||
JP2016503786A5 (ja) | ||
JP2014511891A5 (ja) | ||
JP2014521735A5 (ja) | ||
JP2017528503A5 (ja) | ||
JP2012530705A5 (ja) | ||
JP2015145426A5 (ja) | ||
JP2017528507A5 (ja) | ||
JP2014511892A5 (ja) | ||
JP2017504635A5 (ja) | ||
JP2015024998A5 (ja) | ||
JP2017222722A5 (ja) | ||
JP2016515582A5 (ja) | ||
JP2012502885A5 (ja) | ||
JP2014502979A5 (ja) | ||
JP2014505107A5 (ja) | ||
JP2016523260A5 (ja) | ||
HRP20191121T1 (hr) | Tretman multiple skleroze | |
JP2017517538A5 (ja) | ||
JP2012507535A5 (ja) | ||
JP2016522254A5 (ja) | ||
JP2018537507A5 (ja) |